12:00 PM EST - Zymeworks Inc. : Has initiated its global multicenter Phase 2 clinical trial evaluating ZW25 in combination with standard of care chemotherapy for the first-line treatment of HER2-positive metastatic gastric, gastroesophageal junction, and esophageal adenocarcinomas. Zymeworks Inc.
shares T.ZYME are trading down $0.03 at $20.23.
